These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26960405)

  • 61. Availability of age-appropriate paediatric formulations in the Netherlands: the need in daily clinical practice remains.
    van der Vossen A; Buljaç S; Akçay K; Brugma JD; Vulto A; Hanff L
    Eur J Hosp Pharm; 2021 Nov; 28(6):306-312. PubMed ID: 34697046
    [TBL] [Abstract][Full Text] [Related]  

  • 62. From single excipients to dual excipient platforms in dry powder inhaler products.
    Shur J; Price R; Lewis D; Young PM; Woollam G; Singh D; Edge S
    Int J Pharm; 2016 Dec; 514(2):374-383. PubMed ID: 27262269
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetics of cyclodextrins and drugs after oral and parenteral administration of drug/cyclodextrin complexes.
    Loftsson T; Moya-Ortega MD; Alvarez-Lorenzo C; Concheiro A
    J Pharm Pharmacol; 2016 May; 68(5):544-55. PubMed ID: 26059798
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Phosphate Content of Prescription Medication: A New Consideration.
    Sherman RA; Ravella S; Kapoian T
    Ther Innov Regul Sci; 2015 Nov; 49(6):886-889. PubMed ID: 30222371
    [TBL] [Abstract][Full Text] [Related]  

  • 65. An investigation into the effects of excipient particle size, blending techniques and processing parameters on the homogeneity and content uniformity of a blend containing low-dose model drug.
    Alyami H; Dahmash E; Bowen J; Mohammed AR
    PLoS One; 2017; 12(6):e0178772. PubMed ID: 28609454
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sugar content, cariogenicity, and dental concerns with commonly used medications.
    Donaldson M; Goodchild JH; Epstein JB
    J Am Dent Assoc; 2015 Feb; 146(2):129-33. PubMed ID: 25637211
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sterile Basics: Intravenous Admixture Preparation Considerations, Part 4: Particulates.
    Allen LV
    Int J Pharm Compd; 2020; 24(3):215-220. PubMed ID: 32401741
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pediatric Safety of Polysorbates in Drug Formulations.
    Kriegel C; Festag M; Kishore RSK; Roethlisberger D; Schmitt G
    Children (Basel); 2019 Dec; 7(1):. PubMed ID: 31877624
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An accurate and precise representation of drug ingredients.
    Hanna J; Bian J; Hogan WR
    J Biomed Semantics; 2016; 7():7. PubMed ID: 27096073
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sweeteners, dyes, and other excipients in vitamin and mineral preparations.
    Kumar A; Aitas AT; Hunter AG; Beaman DC
    Clin Pediatr (Phila); 1996 Sep; 35(9):443-50. PubMed ID: 8877241
    [TBL] [Abstract][Full Text] [Related]  

  • 71. PreScription: Standardized Concentrations: Pro or Con?
    Allen LV
    Int J Pharm Compd; 2018; 22(6):444. PubMed ID: 30384343
    [No Abstract]   [Full Text] [Related]  

  • 72. Compounding with Silicones.
    Allen LV
    Int J Pharm Compd; 2015; 19(3):223-30. PubMed ID: 26714363
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Excipient-drug interactions in parenteral formulations.
    Akers MJ
    J Pharm Sci; 2002 Nov; 91(11):2283-300. PubMed ID: 12379914
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement.
    Sanganwar GP; Sathigari S; Babu RJ; Gupta RB
    Eur J Pharm Sci; 2010 Jan; 39(1-3):164-74. PubMed ID: 19961931
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A High-Demanding Strategy to Ensure the Highest Quality Standards of Oral Liquid Individualized Medicines for Pediatric Use.
    Suárez-González J; Santoveña-Estévez A; Armijo-Ruíz S; Castillo A; Fariña JB
    AAPS PharmSciTech; 2019 Jun; 20(5):208. PubMed ID: 31161450
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Anaphylaxis to Excipients in Current Clinical Practice: Evaluation and Management.
    Bruusgaard-Mouritsen MA; Nasser S; Garvey LH; Krantz MS; Stone CA
    Immunol Allergy Clin North Am; 2022 May; 42(2):239-267. PubMed ID: 35469617
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients.
    Radke PW; Joner M; Joost A; Byrne RA; Hartwig S; Bayer G; Steigerwald K; Wittchow E
    EuroIntervention; 2011 Oct; 7(6):730-7. PubMed ID: 21986331
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Potential pharmacokinetic interaction between orally administered drug and osmotically active excipients in pediatric polypharmacy.
    Matsui K; Nakagawa T; Okumura T; Yamane M; Tokunaga Y; Yokota S
    Eur J Pharm Sci; 2021 Oct; 165():105934. PubMed ID: 34256099
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Gluten content of medications.
    Cruz JE; Cocchio C; Lai PT; Hermes-DeSantis E
    Am J Health Syst Pharm; 2015 Jan; 72(1):54-60. PubMed ID: 25511839
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Are excipients really inert ingredients? A review of adverse reactions to excipients in oral dermatologic medications in Canada.
    Noiles K; Vender R
    J Cutan Med Surg; 2010; 14(3):105-14. PubMed ID: 20487670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.